During Tuesday’s Current trade, Shares of MiMedx Group Inc (NASDAQ:MDXG), gain 0.32% to $9.40.
MiMedx Group, Inc. (MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, declared recently that its latest peer-reviewed scientific study, “Dehydrated Human Amnion/Chorion Membrane Regulates Stem Cell Activity In Vitro,” was electronically published in the Journal of Biomedical Materials Research: Part B – Applied Biomaterials.
The electronic publication of the peer-reviewed article is now accessible in the Wiley Online Library and can be found at http://onlinelibrary.wiley.com/doi/10.1002/jbm.b.33478/abstract. The paper was authored by Michelle Massee; Kathryn Chinn; Jennifer Lei; Jeremy J. Lim, PhD; Conan S. Young, PhD; and Thomas J. Koob, PhD. The hard copy publication is predictable to follow in a future issue of the Journal of Biomedical Materials Research: Part B – Applied Biomaterials.
MiMedx Group, Inc. develops, processes, and markets patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Its biomaterial platform technologies are AmnioFix, EpiFix, and CollaFix. The company’s AmnioFix and EpiFix are tissue technologies processed from human amniotic membrane derived from donated placentas.
Shares of Incyte Corporation (NASDAQ:INCY), declined -0.64% to $103.27, during its current trading session.
Incyte Corporation ( INCY) stated 2015 second-quarter financial results, counting revenue from Jakafi.
The Company highlighted the continued momentum in the commercialization of Jakafi in the U.S., in addition to progress being made across its clinical portfolio, counting the results of two pivotal trials of baricitinib that were presented with Eli Lilly and Company (“Lilly”) at the 2015 European League Against Rheumatism (EULAR) meeting in June. In addition, positive proof-of-concept results from the novel:novel combination of Incyte’s PI3Kδ inhibitor INCB40093 and JAK1-selective inhibitor INCB39110 in B-cell malignancies were presented at both the 2015 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings in the second quarter of 2015.
2015 Second-Quarter Financial Results
Revenues For the quarter ended June 30, 2015, net product revenues of Jakafi were $142 million as contrast to $84 million for the same period in 2014, representing 69 percent growth. For the six months ended June 30, 2015, net product revenues of Jakafi were $258 million as contrast to $154 million for the same period in 2014, representing 68 percent growth. For the quarter and six months ended June 30, 2015, product royalties from sales of Jakavi® (ruxolitinib) outside of the United States received from Novartis, the Company’s collaborator, were $17 million and $33 million, respectively, as contrast to $12 million and $22 million, respectively, for the same periods in 2014. For the quarter ended June 30, 2015, contract revenues were $3 million as contrast to $3 million for the same period in 2014. For the six months ended June 30, 2015, contract revenues were $31 million as contrast to $13 million for the same period in 2014. The $18 million enhance in contract revenues for the six months ended June 30, 2015 contrast to the same period in 2014 relates to an enhance in milestone payments earned from Novartis. For the quarter ended June 30, 2015, total revenues were $163 million as contrast to $100 million for the same period in 2014. For the six months ended June 30, 2015, total revenues were $322 million as contrast to $189 million for the same period in 2014.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. It offers JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), counting primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line comprises ruxolitinib, which is in Phase III clinical trial for pancreatic cancer; and in Phase II trial for the treatment of breast cancer, non-small cell lung cancer, and colorectal cancer, in addition to INCB39110 that is in Phase I/II trial for malignancies; and in Phase II trial for non-small cell lung cancer.
Bunge Ltd (NYSE:BG), during its Tuesday’s current trading session decreased -0.47% to $76.63.
Bunge Limited (BG), a global agribusiness and food company, recently declared that its Board of Directors has declared a regular quarterly cash dividend of $0.38 per common share. The dividend is payable on December 2, 2015 to shareholders of record on November 16, 2015.
The company also declared a quarterly cash dividend of $1.21875 per share on its 4.875% cumulative convertible perpetual preference shares, payable on December 1, 2015 to shareholders of record on November 15, 2015.
Bunge Limited, through its auxiliaries, operates as an agribusiness and food company worldwide. It operates in five segments: Agribusiness, Edible Oil Products, Milling Products, Sugar and Bioenergy, and Fertilizer. The Agribusiness segment engages in the purchase, storage, transport, processing, and sale of agricultural commodities and commodity products, such as oilseeds and grains, counting soybeans, rapeseed, canola, sunflower seeds, wheat, and corn to animal feed manufacturers, livestock producers, wheat and corn millers, other oilseed processors, third-party edible oil processing companies, and biodiesel industries. T
Finally, Vishay Intertechnology (NYSE:VSH), decreased -1.47%, to $10.76.
Vishay Intertechnology, (VSH), one of the world’s largest manufacturers of discrete semiconductors and passive components, recently declared its results for the fiscal quarter and six fiscal months ended July 4, 2015.
Revenues for the fiscal quarter ended July 4, 2015 were $590.5 million, contrast to $641.9 million for the fiscal quarter ended June 28, 2014. The net earnings attributable to Vishay stockholders for the fiscal quarter ended July 4, 2015 were $26.3 million, or $0.17 per diluted share, contrast to $35.6 million, or $0.23 per diluted share for the fiscal quarter ended June 28, 2014.
Net earnings attributable to Vishay stockholders for the fiscal quarter ended July 4, 2015 comprises restructuring and severance costs of $5.7 million. Net earnings attributable to Vishay stockholders for the fiscal quarter ended June 28, 2014 comprise restructuring and severance costs of $9.0 million. These items are summarized on the attached reconciliation plan. Adjusted earnings per diluted share, which exclude these items, were $0.20 and $0.27 for the fiscal quarters ended July 4, 2015 and June 28, 2014, respectively.
Vishay Intertechnology, Inc. manufactures and supplies discrete semiconductors and passive components in the United States, Europe, and Asia. The company operates in five segments: MOSFETs, Diodes, Optoelectronic Components, Resistors & Inductors, and Capacitors. The MOSFETs segment offers low- and medium-voltage TrenchFET MOSFETs, high-voltage planar MOSFETs, high voltage Super Junction MOSFETs, power integrated circuits, and integrated function power devices. The Diodes segment provides rectifiers, small signal diodes, protection diodes, thyristors/silicon-controlled rectifiers, and power modules.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
